Novo Nordisk A/S $NVO Stock Position Lowered by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 12.0% during the 3rd quarter, HoldingsChannel reports. The firm owned 462,940 shares of the company’s stock after selling 63,294 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Novo Nordisk A/S were worth $25,689,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. True Wealth Design LLC raised its position in Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after buying an additional 300 shares during the period. Guerra Advisors Inc purchased a new position in Novo Nordisk A/S during the 3rd quarter valued at about $25,000. Strengthening Families & Communities LLC acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at about $30,000. NewSquare Capital LLC boosted its holdings in shares of Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the period. Finally, Mid American Wealth Advisory Group Inc. purchased a new position in Novo Nordisk A/S during the second quarter valued at approximately $37,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: EU approves higher Wegovy dose — the European Commission approved a 7.2 mg maintenance dose of Wegovy after a study showing ~21% average weight loss over ~18 months, which should support uptake and revenue in EU markets. Article Title
• Positive Sentiment: Pipeline beef-up — Novo initiated/updated a Phase‑2 study for UBT251 in obesity, broadening its obesity pipeline and signalling continued R&D investment that could produce future revenue streams. Article Title
• Positive Sentiment: Promising next‑gen drugs — coverage notes a new diabetes candidate that may outperform current semaglutide medicines, offering medium‑term upside if clinical/launch execution succeeds. Article Title
• Positive Sentiment: Share repurchase program — Novo launched repurchases as part of a DKK 15 billion program, which can support EPS and share demand. Article Title
• Neutral Sentiment: Analyst/valuation viewpoint — commentary suggests the stock could have upside due to a materially lower forward P/E and the potential for a sales surprise later this year, but this view depends on execution and a recovery in 2027. Article Title
• Negative Sentiment: Near‑term demand and guidance concerns — coverage highlights a recent ~21% drop over the past month tied to weak 2026 guidance, slowing semaglutide sales and rising competition, which are primary reasons the stock is under pressure today. Article Title

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, February 5th. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Finally, TD Cowen reissued a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $56.07.

Novo Nordisk A/S Trading Down 0.5%

Shares of NYSE:NVO opened at $49.30 on Wednesday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The stock’s 50-day moving average is $53.86 and its 200-day moving average is $53.27. The company has a market cap of $220.12 billion, a P/E ratio of 14.21 and a beta of 0.67. Novo Nordisk A/S has a 52-week low of $43.08 and a 52-week high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 23.63%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.